ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer Clinical Trial

Official title:

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03733119
• Other study ID #: UW17107
• Secondary ID: 2018-0252A534260
• Status: Terminated
• Phase: Phase 2
• Start date: November 13, 2018
• Est. completion date: February 13, 2021

Study information

• Verified date: February 2022
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well Akt/ERK inhibitor ONC201 (ONC201) with a methionine-restricted (MR) diet works in treating participants with triple negative breast cancer that has spread to other places in the body or cannot be removed by surgery. ONC201 activates a process that leads to the death of a cell. ONC201 is able to target tumor cells to get rid of them, but does not affect normal cells. MR diet is a methionine-free amino acid modified medical food. The addition of an intermittent MR diet may enhance the activity of ONC201. Giving ONC201 and an MR diet may work better in treating participants with breast cancer.

Description:

PRIMARY OBJECTIVES:

I. To determine objective response rate (ORR) to ONC201 with a methionine-restricted diet in patients with metastatic triple negative breast cancer (TNBC).

SECONDARY OBJECTIVES:

I. To determine progression-free survival (PFS) to ONC201 with a methionine-restricted diet in patients with metastatic TNBC.

II. To determine clinical benefit rate (complete or partial response plus stable disease) (CBR) at 4 months to ONC201 with a methionine-restricted diet in patients with metastatic TNBC.

III. To determine overall survival (OS) to ONC201 with a methionine-restricted diet in patients with metastatic TNBC.

IV. To assess metabolic indices in patients with metastatic TNBC treated with ONC201 and a methionine-restricted diet.

V. To assess the expression of TRAIL receptor in circulating tumor cells (CTCs) prior, during and upon progression in patients with metastatic TNBC treated with ONC201 with a methionine-restricted diet.

EXPLORATORY OBJECTIVES:

I. To determine time to development of brain metastases or worsening of brain metastases in patients with metastatic TNBC treated with ONC201 with a methionine-restricted diet.

STUDY DESIGN Patients with metastatic TNBC will be enrolled in a single-arm study evaluating ONC201 with a methionine-restricted diet.

After completion of study treatment, participants are followed up every 3 months for 2 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 13, 2021
• Est. primary completion date: February 13, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Metastatic or unresectable TNBC (estrogen receptor [ER] < 10%, progesterone receptor [PR] < 10% and HER2 negative either by immunohistochemistry [IHC] or in situ hybridization method by American Society of Clinical Oncology [ASCO]-College of American Pathologists [CAP] guidelines). For patients with a previous tumor sample with positive ER, PR and/or HER2 results, if the most recent biopsy meets study criteria, they will be eligible.

• Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. within 28 days prior to registration

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately

• Any number of prior lines of systemic therapy for metastatic disease

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

• Prior cancer treatment, including radiotherapy, must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen to =< grade 1 or to baseline prior to initiation of that therapy. Grade 2 or higher exceptions include alopecia, up to grade 2 neuropathy, and other grade 2 AEs or lab values not constituting a safety risk in the opinion of the treating physician. This criteria does not apply to lab tests for normal organ and marrow function outlined below.

• No active central nervous system (CNS) metastatic disease; subjects with prior definitive treatment of their CNS disease by surgical resection, stereotactic body radiation therapy (SBRT) or whole-brain radiotherapy (WBRT) > 28 days ago will be eligible if asymptomatic and off systemic steroids

• Life expectancy of greater than 12 weeks

• Normal organ and marrow function as defined per protocol definitions

• Absolute neutrophil count (ANC) > 1.5 x 10^3/uL

• Platelet count >= 100 x 10^3/uL

• Hemoglobin >= 9 g/dL

• Total bilirubin < 1.5 x upper limit of normal (ULN)

• Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) = 2.5 x ULN if participant has liver metastases, =5x ULN.

• Creatinine < ULN (institutional normal)

• Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or they are naturally postmenopausal for at least 12 consecutive months

• Females of childbearing potential must be willing to abstain from heterosexual activity or must agree to use adequate contraception (hormonal or barrier method) for the duration of study participation and for 90 days after discontinuation of study treatment

• Ability of the subject to understand and comply with study procedures for the entire length of the study

• Able to swallow ONC201

• Be willing to discontinue vitamin and mineral supplements for the duration of the study if randomized to receive the methionine restricted diet

Exclusion Criteria:

• No prior therapy with TRAIL receptor agonists

• Active infection requiring systemic therapy. Patients with a known history of human immunodeficiency virus (HIV) must have a CD4 count >= the institutional lower limit of normal within 28 days prior to registration. Patients with HIV must also be on a stable antiretroviral regimen for >= 28 days before registration

• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)

• Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least three years

• Treatment with any investigational drug agent =< 14 days prior to registration or within 5 half-lives of that investigational product, whichever is longer

• Participant who has had major surgery =< 14 days prior to registration or has not recovered from major side effects of the surgery (tumor biopsy is not considered as major surgery)

• Known hypersensitivity to any of the excipients of ONC201

• Any impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

• Any concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate subject participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)

• Participants who follow a vegan or vegetarian diet

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Akt/ERK Inhibitor ONC201
Given PO

Dietary Supplement:
• Methionine-Restricted Diet
Given PO

Locations

Country	Name	City	State
United States	University of Wisconsin Carbone Cancer Center	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
University of Wisconsin, Madison	The V Foundation for Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Time to Development or Worsening of Brain Metastases	Will be summarized using Kaplan-Meier methodology.	Up to 2 years
Other	Number of Participants With Developing or Worsening Brain Metastasis		up to 4 months
Primary	Overall Response Rate (ORR) - Number of Participants Who Responded to Treatment	ORR will be estimated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, by dividing the total number of responders (complete plus partial responses plus CR or PR) or (CR or PR), respectively, by number of subjects with measurable disease and the exact 95% confidence interval will be provided.; Due to early termination with few participants, only the counts of events have been reported.	maximum follow up time was 1 year
Secondary	Progression-free Survival (PFS) - Number of Participants With PFS	Will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided.; Due to early termination with few participants, only the counts of events have been reported.	maximum follow up time was 1 year
Secondary	Overall Survival (OS) - Number of Participants Who Survived the Study Period	Will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided.; Due to early termination with few participants, only the counts of events have been reported.	maximum follow up time was 1 year
Secondary	Clinical Benefit Rate (CBR) - Number of Participants Who Experienced Clinical Benefit	CBR will be estimated according to RECIST 1.1, by dividing the total number of responders (complete plus partial responses plus CR or PR or stable disease [SD]), by number of subjects with measurable disease and the exact 95% confidence interval will be provided.; Due to early termination with few participants, only the counts of events have been reported.	At 4 months
Secondary	Duration of Response (DOR)	Will be measured using Kaplan-Meier methodology. A 95% confidence interval will be provided for the median duration of response.	Up to 2 years
Secondary	Incidence of Adverse Events - Number of Participants Who Experienced Adverse Events	Incidence of adverse events as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0. Safety and tolerability will be assessed by frequency tables. Also, metabolic indices in patients with metastatic triple negative breast cancer (TNBC) treated with ONC-201 and a methionine-restricted diet will be assessed by frequency tables and descriptive statistics.	30 days after last dose of study drug, up to 4 months on study

External Links

•   University of Wisconsin Carbone Cancer Center